Zai Lab Ltd
ZLAB37.910USD
+1.090+2.96%
交易中 （美东）报价延迟15分钟
4.11B总市值
亏损市盈率 TTM
关于 Zai Lab Ltd 公司
再鼎医药是一家主要从事生物制药的控股公司。公司致力于通过产品发现、开发和商业化来解决肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病领域尚未满足的医疗需求。公司拥有一系列从发现阶段到后期临床项目的专利候选药物。其中包括 ZEJULA、OPTUNE、QINLOCK、NUZYRA 和 VYVGART 等。
公司简介
公司代码ZLAB
公司名称Zai Lab Ltd
上市日期Sep 28, 2020
CEODr. Du (Samantha) Ying, Ph.D.
员工数量1869
证券类型Depository Receipt
年结日Sep 28
公司地址Building B, 899 Halei Road, Pudong
城市SHANGHAI
上市交易所NASDAQ Global Market Consolidated
国家China
邮编201203
电话862161632588
网址https://www.zailaboratory.com/
公司代码ZLAB
上市日期Sep 28, 2020
CEODr. Du (Samantha) Ying, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
67.34K
+55.78%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
21.00K
-22.34%
Dr. Du (Samantha) Ying, Ph.D.
Dr. Du (Samantha) Ying, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Dr. Richard B. Gaynor, M.D.
Dr. Richard B. Gaynor, M.D.
Independent Director
Independent Director
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
67.34K
+55.78%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
21.00K
-22.34%
Dr. Du (Samantha) Ying, Ph.D.
Dr. Du (Samantha) Ying, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
业务USD
名称
营收
占比
ZEJULA
49.53M
46.88%
VYVGART
18.11M
17.14%
NUZYRA
15.12M
14.31%
Optune
11.36M
10.76%
QINLOCK
8.51M
8.05%
Other
3.03M
2.86%
暂无数据
业务
地区
业务USD
名称
营收
占比
ZEJULA
49.53M
46.88%
VYVGART
18.11M
17.14%
NUZYRA
15.12M
14.31%
Optune
11.36M
10.76%
QINLOCK
8.51M
8.05%
Other
3.03M
2.86%
股东统计
更新时间: 8月3日 周日
更新时间: 8月3日 周日
持股股东
股东类型
持股股东
持股股东
占比
Capital World Investors
5.41%
Fidelity Management & Research Company LLC
4.21%
Janus Henderson Investors
3.43%
Wellington Management Company, LLP
3.28%
ClearBridge Investments, LLC
2.95%
Other
80.71%
持股股东
持股股东
占比
Capital World Investors
5.41%
Fidelity Management & Research Company LLC
4.21%
Janus Henderson Investors
3.43%
Wellington Management Company, LLP
3.28%
ClearBridge Investments, LLC
2.95%
Other
80.71%
股东类型
持股股东
占比
Investment Advisor
20.70%
Investment Advisor/Hedge Fund
19.15%
Hedge Fund
5.67%
Research Firm
2.88%
Individual Investor
1.42%
Venture Capital
1.39%
Pension Fund
0.67%
Private Equity
0.32%
Sovereign Wealth Fund
0.18%
Other
47.63%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
393
64.25M
57.85%
-6.53M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
2023Q3
537
44.27M
45.68%
-20.42M
2023Q2
568
47.21M
48.74%
-23.76M
2023Q1
572
60.29M
61.61%
-11.82M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
6.01M
5.41%
-425.00K
-6.61%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.68M
4.21%
+945.91K
+25.33%
Mar 31, 2025
Janus Henderson Investors
3.81M
3.43%
-2.75M
-41.94%
Mar 31, 2025
Wellington Management Company, LLP
3.65M
3.28%
-3.01M
-45.22%
Mar 31, 2025
ClearBridge Investments, LLC
3.28M
2.95%
+1.42M
+76.05%
Mar 31, 2025
RTW Investments L.P.
3.14M
2.82%
+627.56K
+25.01%
Mar 31, 2025
Principal Global Investors (Equity)
2.88M
2.6%
+1.12M
+63.64%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.45M
2.2%
-532.32K
-17.86%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.27M
2.04%
-85.81K
-3.65%
Mar 31, 2025
Baron Capital Management, Inc.
1.83M
1.65%
-79.59K
-4.17%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Tema Oncology ETF
3.06%
ALPS Medical Breakthroughs ETF
2.67%
Virtus LifeSci Biotech Products ETF
1.57%
Invesco Golden Dragon China ETF
1.14%
Innovator IBD 50 Fund ETF
0.94%
National Security Emerging Markets Index ETF
0.43%
iShares Biotechnology ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
Capital Group New Geography Equity ETF
0.21%
查看更多
Tema Oncology ETF
占比3.06%
ALPS Medical Breakthroughs ETF
占比2.67%
Virtus LifeSci Biotech Products ETF
占比1.57%
Invesco Golden Dragon China ETF
占比1.14%
Innovator IBD 50 Fund ETF
占比0.94%
National Security Emerging Markets Index ETF
占比0.43%
iShares Biotechnology ETF
占比0.25%
ProShares Ultra Nasdaq Biotechnology
占比0.23%
Invesco Nasdaq Biotechnology ETF
占比0.23%
Capital Group New Geography Equity ETF
占比0.21%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
